ROCKET PHARMACEUTICALS, INC.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Research and development | $142.0M | $171.2M | $186.3M | $165.6M | $125.5M |
| Operating expenses | $231.7M | $273.2M | $259.7M | $224.3M | $167.2M |
| Operating income | -$231.7M | -$273.2M | -$259.7M | -$224.3M | -$167.2M |
| Interest expense | $1.9M | $1.9M | $1.9M | $1.9M | $3.0M |
| Pretax income | -$223.1M | -$258.7M | — | — | — |
| Income tax expense | $0 | $0 | $0 | — | — |
| Net income | -$223.1M | -$258.7M | -$245.6M | -$221.9M | -$169.1M |
| Balance Sheet | |||||
| Cash and equivalents | $77.6M | $163.6M | $55.9M | $140.5M | $232.7M |
| Current assets | $192.7M | $378.2M | $378.2M | $364.1M | $392.1M |
| Total assets | $330.4M | $527.7M | $566.3M | $551.8M | $497.0M |
| Current liabilities | $30.2M | $40.7M | $48.5M | $39.2M | $22.2M |
| Total liabilities | $53.2M | $64.5M | $73.8M | $62.1M | $42.3M |
| Stockholders' equity | $277.2M | $463.2M | $492.6M | $489.7M | $454.7M |
| Cash Flow Statement | |||||
| Cash from operations | -$190.0M | -$209.7M | -$194.9M | -$178.1M | -$121.2M |
| Depreciation and amortization | $8.9M | $7.2M | $4.9M | $3.9M | $3.2M |
| Stock-based compensation | $37.1M | $43.9M | $39.4M | $31.0M | $29.2M |
| Capital expenditure | $440,000 | $5.9M | $16.4M | $8.4M | $7.6M |
| Free cash flow | -$190.5M | -$215.6M | -$211.4M | -$186.5M | -$128.8M |
| Share repurchases | — | — | — | — | $0 |
| Impairments | $0 | $0 | $0 | $0 | $0 |
Shares outstanding 109.2M · Free float 78.2%
Annual filing data through FY ended December 31, 2025; float as of July 12, 2026.